Fig. 2From: Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experiencePercentage of patients reporting a > 50% reduction in headache attacks frequency, pain intensity, headache attacks duration and “whole pain burden” score at the end of the third (T1) and sixth month (T2) galcanezumab administrationsBack to article page